Molecules 2009, 14(10), 4166-4179; doi:10.3390/molecules14104166
Article

Design and Synthesis of Novel 2-Phenylaminopyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells

1 Shenyang Pharmaceutical University, Shenyang, 110016, China 2 Mount Sinai School of Medicine, New York, NY 10029, USA
* Author to whom correspondence should be addressed.
Received: 1 September 2009; in revised form: 30 September 2009 / Accepted: 12 October 2009 / Published: 19 October 2009
PDF Full-text Download PDF Full-Text [381 KB, uploaded 19 October 2009 11:09 CEST]
Abstract: A series of novel 2-phenylaminopyrimidine (PAP) derivatives structurally related to STI-571 were designed and synthesized. The abilities of these compounds to inhibit proliferation were tested in human chronic myeloid leukemia K562 cells. (E)-3-(2-bromophenyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]acrylamide(12d) was the most effective cell growth inhibitor and was 3-fold more potent than STI-571.
Keywords: 2-Phenylaminopyrimidine (PAP) derivative; STI-571; antiproliferative activity

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Chang, S.; Yin, S.-L.; Wang, J.; Jing, Y.-K.; Dong, J.-H. Design and Synthesis of Novel 2-Phenylaminopyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells. Molecules 2009, 14, 4166-4179.

AMA Style

Chang S, Yin S-L, Wang J, Jing Y-K, Dong J-H. Design and Synthesis of Novel 2-Phenylaminopyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells. Molecules. 2009; 14(10):4166-4179.

Chicago/Turabian Style

Chang, Sheng; Yin, Shi-Liang; Wang, Jian; Jing, Yong-Kui; Dong, Jin-Hua. 2009. "Design and Synthesis of Novel 2-Phenylaminopyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells." Molecules 14, no. 10: 4166-4179.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert